The 7 Biggest Mistakes North American Cannabis Companies Make When Entering Europe

The problem with the export mindset

A cannabis or cannabinoid business that works in Denver, Toronto or Los Angeles has usually solved a specific set of problems: a licence regime it understands, a retail channel it can reach, and a product that a state or federal regulator already accepts. None of that travels.

Europe is not one cannabis market. There is no single European cannabis law. Some rules are set at EU level and apply across all member states, some are purely national, and several of the rules that decide whether your product can be sold at all sit in frameworks that have nothing to do with cannabis policy — food law, medicines law, cosmetics law, customs.

Switzerland and the UK are not in the EU at all, which changes customs, VAT and regulatory responsibility before you get to strategy. Two neighbouring countries can be opposite answers for the same product.

The seven mistakes below are the ones that show up most often when a North American company starts looking at Europe. They are not exotic. They are ordinary sequencing errors that get expensive.

Mistake 1 — Treating Europe as one market

"We're entering Europe" is not a decision. It is a category of decisions, and each country inside it behaves differently.

Medical cannabis is regulated nationally. Germany moved medical cannabis out of narcotics law into the Medical Cannabis Act (MedCanG), in force since 1 April 2024, and has since debated further amendments to prescribing and distribution — a reminder that even a mature market keeps moving. The Netherlands runs a controlled cannabis supply-chain experiment in which participating coffeeshops source regulated cannabis from designated growers. It should not be treated as a conventional import opportunity for North American recreational cannabis producers, and it does not represent the Dutch market as a whole. Adult-use commercial sale is not legal EU-wide; the countries that have moved have done so through domestic, largely non-commercial models.

For cannabinoid consumer products, the differences are just as sharp. National authorities take different positions on THC thresholds in finished products, on what may be sold as a food supplement, and on how strictly they enforce.

Practical consequence: market maturity, channel structure, price levels and enforcement culture all differ. So the first market you choose is not a detail — it determines your cost of entry and how long it takes to learn anything useful. We cover the selection logic in Choosing the Right European Cannabis Market and at a market level on the European cannabis market page.

Mistake 2 — Choosing the country before understanding the regulatory pathway

Most North American companies start with a country. Germany looks big. Spain looks open. The Netherlands sounds permissive. That order is backwards.

A more reliable sequence is: product → legal category → regulatory pathway → market feasibility → commercial model → country.

• Medical cannabis: a medicines and controlled-substances question. Licensing, pharmaceutical quality requirements and import permissions are national, and the buyer is a regulated supply chain, not a retailer.
• CBD and other cannabinoid ingestibles can raise EU food-law and Novel Food issues, with national rules and enforcement positions also affecting marketability.
• Cosmetics: EU-harmonised under Regulation (EC) 1223/2009, which requires a Responsible Person established in the EU, a safety assessment and notification before placing on the market — a different pathway entirely, with different ingredient constraints.
• Industrial hemp raw material: an agricultural framework. The 0.3% THC figure often quoted is the maximum THC content for hemp varieties eligible under EU agricultural rules (raised from 0.2% with effect from 2023) — it is a crop and variety threshold, not a universal THC limit for finished consumer products, which differ by country and product category.

The same company, three different answers

One business with a gummy, a topical and a bulk isolate is running three separate regulatory projects, potentially in three different countries, with three different timelines. Treating them as one "Europe launch" is how budgets disappear.

This is where the sequencing work belongs: regulatory and compliance strategy first, then product development decisions, then country shortlisting against individual markets.

Mistake 3 — Assuming North American compliance transfers to Europe

A product that is compliant in Colorado or under Canadian federal rules is not automatically placeable on any European market. Compliance is not a property of the product; it is a property of the product in a specific legal category in a specific country.

The clearest example is CBD in food and supplements. Foods containing added cannabinoids such as CBD can raise Novel Food issues under Regulation (EU) 2015/2283. Whether a specific product falls within the Novel Food framework depends on factors including its composition, production process and intended use. Where the Novel Food framework applies, authorisation and inclusion on the Union list are required before lawful placing on the market. That route has not delivered for CBD. EFSA identified significant data gaps in 2022, and from February 2026 onwards the Commission adopted a series of implementing decisions terminating CBD novel food applications without updating the Union list. On 9 February 2026 EFSA published an updated statement setting a provisional safe intake level for CBD of 0.0275 mg per kg of body weight per day (roughly 2 mg a day for a 70 kg adult) while noting persistent data gaps — a provisional safety level, not an authorisation. In a May 2026 opinion on a CBD isolate intended for food supplements, EFSA concluded that the safety of the novel food under the proposed conditions of use could not be established.

Read that commercially, not legally: as of writing no CBD novel food has been added to the Union list, national enforcement varies widely, and a supplement business model built on assumed EU-wide legality is exposed. Separately, in Case C-663/18 (Kanavape, judgment of 19 November 2020) the Court of Justice held that CBD lawfully produced in one member state is not a narcotic drug under the 1961 Convention, and that a national marketing ban can be an unjustified restriction on the free movement of goods unless it is justified on public-health grounds and proportionate. That judgment concerned a national prohibition; it did not create EU-wide approval for CBD products. Neither point makes a CBD food automatically marketable.

• Ingredients: excipients, sweeteners, flavourings and additives permitted in North America are not automatically permitted in EU food or cosmetics.
• Classification: the same formulation can be a food, a supplement, a cosmetic, a medical device or a medicine depending on presentation, dose and claims.
• Claims: health and nutrition claims on foods are tightly controlled at EU level; most wellness language used in US marketing cannot be carried over.
• Labelling: language requirements, mandatory particulars and responsible-operator details are country- and category-specific.
• THC content in finished products: limits and testing expectations differ by country and category. Verify per market, per product.

Mistake 4 — Assuming distribution works the same way

North American route to market is usually built around licensed retail inside one jurisdiction. In Europe, for most non-medical categories, you are dealing with an import and wholesale structure: an importer or local entity that takes regulatory responsibility, a distributor with channel relationships, then wholesalers and retailers with their own margin expectations.

That structure carries obligations, not just logistics. Someone has to be the legal operator placing the product on the market, holding documentation, handling notifications where required, and answering to the authority. If your distributor is that entity, they hold a significant part of your market position.

Medical cannabis is different again: importers, licensed wholesalers and pharmacies, with pharmaceutical quality and licensing requirements throughout.

There is no universally correct model. Direct is not better than distributor-led, and exclusivity is not automatically bad. The model should be designed around the product, the category and the regulatory structure — which is the argument made in Distribution in Europe and in our distribution strategy work.

Mistake 5 — Choosing a distributor before understanding the market

The most common way a European entry quietly fails: a company meets an enthusiastic distributor at a trade show, signs a multi-country exclusive, ships an opening order, and hears very little afterwards.

A distributor's willingness to buy is not evidence of fit. Ask the unglamorous questions before signing anything.

• Which countries do they actually sell into themselves, and where are they using sub-distributors?
• Which channels do they operate in — pharmacy, specialist retail, grocery, e-commerce, wholesale?
• Which product categories do they already handle, and under which legal classification?
• Do they understand the regulatory requirements for your category, and who performs those tasks?
• Who is the legal operator placing the product on the market, and who holds the technical file?
• Who owns the customer relationship and the data?
• What are the minimum volumes, and what happens if they are not met?
• Is exclusivity requested, over which territories, channels and duration?
• Who carries inventory and the currency, payment and returns risk?
• What does the exit look like — notice periods, registrations, trademarks, remaining stock?

Mistake 6 — Underestimating the economics of entering Europe

Regulatory feasibility and commercial viability are separate tests. A product can be perfectly placeable and still lose money.

There is no standard cost of entering Europe, and anyone quoting one is guessing. What is predictable is the shape of the cost base — and how much of it lands before the first invoice.

• Regulatory and legal review, per category and per country
• Product testing, analysis and documentation
• Reformulation, packaging and multi-language labelling
• Import duties, VAT, freight and customs handling
• Warehousing and local logistics
• Importer, local entity or Responsible Person costs where required
• Distributor and retailer margin through the chain
• Marketing and market development, usually funded by you
• Working capital for inventory sitting in Europe before it sells

Landed cost is the number that matters

Work backwards from the shelf price a European buyer will actually pay, subtract retail and distributor margin, subtract logistics, duties and compliance amortisation, and see what is left for you. If the answer only works at volumes you cannot yet supply, the market is not ready for you — or you are not ready for it.

Our market entry calculator gives an initial view of market attractiveness, regulatory complexity and route to market before you commit budget to a specific country.

Mistake 7 — Trying to scale before proving the first market

Pan-European launch plans look impressive in a board deck and rarely survive contact with two regulators at once. Each additional country multiplies compliance work, partner management and working capital while you still have no proof that the model works anywhere in Europe.

There is no single correct expansion sequence. But the first market should be chosen partly for what it teaches you — whether the product is accepted as formulated, whether the regulatory pathway behaves as advised, whether the partner performs, whether demand is real at your price, and whether the unit economics hold once everything is paid.

If a second market cannot reuse most of what you built in the first — documentation, packaging architecture, partner model, pricing logic — you are not scaling. You are starting again.

Before entering Europe: a North American company's checklist

Ten questions. If you cannot answer them clearly, you are not ready to pick a country.

• What exactly is the product — formulation, format, cannabinoid content, claims?
• How is it legally classified in the target category: food, supplement, cosmetic, medicine, medical device or raw material?
• Which countries can realistically accept it in that classification today?
• What regulatory work is required before placing it on the market, and who does it?
• What product changes may be needed — ingredients, dosage, packaging, labelling, claims?
• What route to market fits: direct, importer, distributor, hybrid?
• Who carries import and compliance responsibility as the legal operator?
• What is the realistic landed cost, and what margin remains at a credible shelf price?
• Which single market will be tested first, and why that one?
• What evidence — commercial and regulatory — will decide whether to expand or stop?

Where this leaves you

Many unsuccessful European entries are not failures of execution. They are failures of selection and sequencing: the wrong country, chosen before the regulatory pathway was understood, served through a partner selected before the market was understood.

Canna Euro Consulting helps international cannabis and cannabinoid businesses assess European markets, regulatory considerations, route-to-market options and commercial strategy. If your company is based in the US or Canada and is evaluating European expansion, the useful first step is narrow: identify which market, which product pathway and which route to market actually make sense for your business — then test that one properly.

Start with an initial market assessment, read the underlying method in our European market entry framework, or tell us what you're planning.

This article is commercial interpretation, not legal advice. Cannabis and cannabinoid rules change frequently and differ by country and product category — verify the current position for your specific product with the relevant national authority before committing.